Clinical Trials Browser

Phase 1 × Carcinoma, Transitional Cell × avelumab × Clear all

NCT04004442 2026-03-13

COAXIN

Phase 1 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT03252938 2026-02-19

INSIGHT

Phase 1 Active not recruiting

GenitourinaryGynecologic

Carcinoma, Transitional Cell, Peritoneal Neoplasms

NCT03575013 2025-12-03

A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer

Phase 1 Completed

Carcinoma, Transitional Cell

NCT03915405 2024-04-25

KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer

Phase 1 Terminated

Carcinoma, Transitional Cell

NCT04601402 2023-08-08

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

Phase 1 Completed

GenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT01772004 2021-12-20

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Phase 1 Completed

1,756 enrolled 59 charts

BreastDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Adrenocortical Carcinoma